Hudson Bay Capital Management
SMMT icon

Hudson Bay Capital Management’s Summit Therapeutics SMMT Stock Holding History

Hudson Bay Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$801K Buy
+54,950
New +$974K ﹤0.01% 958
2026
Q1 		– Sell
-11,440
Closed -$200K – 1578
2025
Q4 		$200K Buy
+11,440
New +$215K ﹤0.01% 970
2024
Q3 		– Sell
-75,000
Closed -$585K – 1021
2024
Q2 		$585K Buy
+75,000
New +$405K ﹤0.01% 637

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Hudson Bay Capital Management's SMMT Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 54,950 shares worth $801K. The stake represents ﹤0.01% of the portfolio and ranks #958 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in SMMT as recently as Q4 2025.

Hudson Bay Capital Management first reported a position in SMMT in Q2 2024 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Hudson Bay Capital Management held 54,950 shares of Summit Therapeutics worth $801K as of Q2 2026.
  • Summit Therapeutics was a new Hudson Bay Capital Management position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #958 holding.
  • Hudson Bay Capital Management first reported a position in Summit Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.